Volvat Medisinske Senter AS

Research siteFast reply

Norway Borgenveien 2a, 0370 Oslo, Norway

Lichen planopilaris
Adult patients

About Specializations

Volvat Medisinske Senter AS in Oslo, Norway specialises in clinical trials of conditions such as Lichen planopilaris, and other specialisations. This site conducts important research.

Lichen planopilaris

Main research areas of the site

Dermatology and Hair Disorders

The medical center is at the forefront of dermatology research, with a particular focus on innovative treatments for hair disorders. The ongoing research into frontal fibrosing alopecia (FFA) exemplifies the center's commitment to addressing complex dermatological conditions.

Frontal Fibrosing Alopecia (FFA)
Microneedling Techniques
Photodynamic Therapy

By exploring the combination of microneedling and photodynamic therapy, the center aims to reduce inflammation and improve patient outcomes, contributing significantly to the advancement of therapeutic strategies in hair loss disorders.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Borgenveien 2a0370 OsloNorway

Open in maps ↗

Recruiting now: no trials
Conditions studied: 1

More sites in Oslo Norway

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Quick filters

1 clinical trial

Lichen planopilaris

Not yet recruiting

Study on Treating Frontal Fibrosing Alopecia in Adults Using Microneedling and Photodynamic Therapy with Methyl Aminolevulinate Hydrochloride

Registered drugNo placebo

Study on Treating Frontal Fibrosing Alopecia in Adults Using Microneedling and Photodynamic Therapy with Methyl Aminolevulinate Hydrochloride

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Methyl Aminolevulinate Hydrochloride
Sponsor:Oslo University Hospital HF

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites